<DOC>
	<DOCNO>NCT02260804</DOCNO>
	<brief_summary>To demonstrate CT-P10 similar Rituxan term efficacy determine overall response rate 7 month</brief_summary>
	<brief_title>To Compare Efficacy Safety Between CT-P10 Rituxan Patients With Low Tumour Burden Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Confirmed diagnosis low tumour burden , CD20+ follicular lymphoma Ann Arbor Stage II , III IV Has receive rituximab Allergies hypersensitivity murine , chimeric , human humanise protein Previous treatment NHL Any malignancy Current recent treatment investigational medicinal product device pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>